This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biogen's MS Pill Roars Out Of Launch Gate

Stocks in this article: BIIB NVS

CAMBRIDGE, Mass. ( TheStreet) -- Biogen Idec's (BIIB) multiple sclerosis pill Tecfidera is off to a blazing commercial launch.

Check out the green, nearly vertical line, in the graph above. It represents one week of Tecfidera scripts, per IMS Health. As ISI Group analyst Mark Schoenebaum points out, Biogen booked as many Tecfidera scripts in one week as Novartis (NVS) did with Gilenya after three months.

Biogen shares are up 4% to $210.73 in early trading.

Yes, we're only looking at a single week of Tecfidera scripts, so it's way too early to reach any definitive conclusions. Still, pretty cool if you're Biogen or one of its shareholders.

"Any way you look at it, BG-12 appears to be doing very well in its inaugural week," writes Schoenebaum in an email to clients Monday morning, referring to Tecfidera's scientific name. Schoenebaum also created and sent out the graph.

Biogen reports first-quarter financial results on Thursday morning, with current consensus at earnins of $1.61 per share on total revenue of $1.42 billion. Tecfidera was approved at the end of March, so sales won't factor much into first-quarter results. Still, investors will definitely want to hear from Biogen management about the early weeks of the launch.

For the year, Biogen is expected to earn $7.79 per share on total revenue of $6.43 billion. Included in the consensus revenue estimate is approximately $240 million in Tecfidera sales.

If that slope of that green line in the graph above remains vertical, investors are under-estimating Tecfidera sales -- and Biogen earnings.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs